The study’s authors, led by Marin Schrappe, MD, of Christian Albrechts University Kiel and University Hospital Schleswig-Holstein in Germany, enrolled pediatric patients with high-risk B-ALL to receive two cycles of either blinatumomab or control chemotherapy after consolidation therapy. The primary end point was EFS based on a time-to-event analysis. 

The authors, led by Nicolas Boissel, MD, PhD, of Hôpital Saint-Louis in Paris, France, analyzed 94 patients with high-risk B-ALL who received up to five cycles of blinatumomab during consolidation and maintenance therapy. A post hoc analysis compared outcomes in these patients with outcomes in 90 control patients treated without blinatumomab before QUEST activation.